{"id":390947,"date":"2017-07-17T00:00:00","date_gmt":"2017-07-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0034-2017-biopharma-asthma-treatment-algorithms-claims-data-analysis-us-2017\/"},"modified":"2026-04-16T11:27:10","modified_gmt":"2026-04-16T11:27:10","slug":"algoim0034-2017-biopharma-asthma-treatment-algorithms-claims-data-analysis-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0034-2017-biopharma-asthma-treatment-algorithms-claims-data-analysis-us-2017\/","title":{"rendered":"Asthma | Treatment Algorithms | Claims Data Analysis | US | 2017"},"content":{"rendered":"<p>MARKET OUTLOOK\u00a0<br \/>\nAsthma pharmacotherapy has two main goals: to address underlying airways inflammation and promote bronchodilation. Physicians use two types of therapy to achieve these goals: maintenance therapy (, a LABA\/ICS, such as GSK\u2019s Advair or AstraZeneca\u2019s Symbicort) and rescue therapy (, a SABA, such as albuterol); and most asthma patients will receive more than one drug to treat their condition. While there are multiple well-established agents available for both maintenance and rescue treatment, over the past two years, the asthma treatment landscape has witnessed the approval of the first once-daily LABA\/ICS (, GSK\u2019s Breo), the first LAMA (, Boehringer Ingelheim\u2019s Spiriva), and the first\u2014in over ten years\u2014biologic (, GSK\u2019s Nucala). The availability of these agents has helped to expand physicians&#8217; treatment armamentarium and fuel increasing competition in the asthma market.\u00a0<\/p>\n<p>PRODUCT DESCRIPTION\u00a0<br \/>\nTreatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.\u00a0<\/p>\n","protected":false},"template":"","class_list":["post-390947","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390947","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390947\/revisions"}],"predecessor-version":[{"id":394071,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390947\/revisions\/394071"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390947"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}